GlaxoSmithKline plc (GSK) PT Set at GBX 1,700 by Morgan Stanley

GlaxoSmithKline plc (LON:GSK) has been given a GBX 1,700 ($22.15) target price by Morgan Stanley in a report released on Thursday. The brokerage presently has a “neutral” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 11.95% from the company’s current price.

Other analysts also recently issued reports about the company. Beaufort Securities upped their price objective on GlaxoSmithKline plc from GBX 1,750 ($22.80) to GBX 2,000 ($26.06) and gave the company a “buy” rating in a research report on Thursday, June 1st. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Friday, June 2nd. Liberum Capital reiterated a “buy” rating and set a GBX 1,900 ($24.75) target price on shares of GlaxoSmithKline plc in a research report on Tuesday, June 6th. S&P Global set a GBX 1,500 ($19.54) price objective on GlaxoSmithKline plc and gave the stock a “sell” rating in a report on Tuesday, June 6th. Finally, Jefferies Group LLC raised their price objective on GlaxoSmithKline plc from GBX 1,800 ($23.45) to GBX 1,900 ($24.75) and gave the stock a “buy” rating in a report on Friday, June 16th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of GBX 1,734.73 ($22.60).

Shares of GlaxoSmithKline plc (GSK) opened at 1518.50 on Thursday. GlaxoSmithKline plc has a 52-week low of GBX 1,446.50 and a 52-week high of GBX 1,745.56. The stock’s market capitalization is GBX 74.19 billion. The firm’s 50 day moving average is GBX 1,638.77 and its 200 day moving average is GBX 1,627.17.

COPYRIGHT VIOLATION WARNING: “[[title]]” was posted by [[site]] and is the property of of [[site]]. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at [[permalink]].

In related news, insider Victoria Whyte sold 4,820 shares of the company’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of GBX 1,693 ($22.06), for a total value of £81,602.60 ($106,308.75). Also, insider Manvinder Singh Banga acquired 2,267 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was purchased at an average price of GBX 1,599 ($20.83) per share, with a total value of £36,249.33 ($47,224.24). In the last three months, insiders bought 3,150 shares of company stock worth $5,054,075.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.